Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L.
Toulemonde E, et al. Among authors: le du f.
Cancer Immunol Immunother. 2023 Aug;72(8):2649-2657. doi: 10.1007/s00262-023-03449-9. Epub 2023 Apr 17.
Cancer Immunol Immunother. 2023.
PMID: 37067554
Free PMC article.